Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the first ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Before diving into the highlights '24, we did put on the 20 years Molecular Partners logo because it is our 20 ... And again, this will be shown at AACR 2025 in late April. So again, very excited ...

By applying the Crossmark logo, the American Association for Cancer Research (AACR) is committing to maintaining the content it publishes and to alerting readers to changes if and when they occur.

Researchers have discovered race-associated molecular differences in tumors that may impact the way patients with pancreatic ...

First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated ...

Brodeur, MD, and Stephan A. Grupp, MD, PhD, have been elected to the 2025 class of Fellows of the American Association for Cancer Research (AACR) Academy. Each year, the Fellows of the AACR ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

The findings, which were recently published in the American Association for Cancer Research (AACR) Journal, reinforce the need to include racially diverse participants in clinical studies.

Sonnet BioTherapeutics Holdings, Inc. announced that its abstract has been accepted for a poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference, scheduled ...

The research, presented at the American Association for Cancer Research (AACR)-IO conference, highlights the potential of IO170, a TGF-β-directed vaccine, which demonstrated significant tumor ...